Notice on the 3rd Extraordinary General Meeting in 2025
Filed with SSE · · 6 pages · Chinese
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Adding Extraordinary Proposal Supplementary Notice of the 2nd Extraordinary General Meeting in 2025
- Announcement on Absence of Financial Assistance or Compensation Provided to the Investors in the Current Private Placement, Either Directly or Through Interested Parties
- Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
Later from Shanghai MicuRx Pharmaceutical
- Report for Q3 2025
- Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
- Announcement on Voluntary Disclosure of the Issuance of Approval Notices for Supplementary Applications for Drugs and Supplementary Applications for Drug Clinical Trials
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
- Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical